In a large clinical trial, researchers found that semaglutide ... proven to lower this cardiovascular risk is a major advance for public health,” John Sharretts, M.D., director of the division of ...

Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The result from the SUMMIT study helps Lilly close the gap with Novo Nordisk, whose GLP-1 agonist semaglutide is already approved to reduce the risk of serious cardiovascular conditions in people ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Nearly 2 in 3 people who sought to lose weight quit popular weight loss and diabetes drugs such as Ozempic or Victoza within one year, according to a new study. About 65% of those without diabetes ...